Please use this identifier to cite or link to this item:
Title: Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents Insights From the Xience V Coronary Stent System Trials
Authors: Genereux, Philippe
Rutledge, David R.
Palmerini, Tullio
Caixeta, Adriano [UNIFESP]
Kedhi, Elvin
Hermiller, James B.
Wang, Jin
Krucoff, Mitchell W.
Jones-McMeans, Jennifer
Sudhir, Krishnankutty
Simonton, Charles A.
Serruys, Patrick W.
Stone, Gregg W.
Columbia Univ
Cardiovasc Res Fdn
Univ Montreal
Abbott Vasc
Univ Bologna
Universidade Federal de São Paulo (UNIFESP)
Hosp Israelita Albert Einstein
Isala Klin
St Vincent Heart Ctr Indiana
Duke Univ
Erasmus Univ Hosp
Keywords: drug-eluting stents
Issue Date: 1-May-2015
Publisher: Lippincott Williams & Wilkins
Citation: Circulation-cardiovascular Interventions. Philadelphia: Lippincott Williams & Wilkins, v. 8, n. 5, 15 p., 2015.
Abstract: Background-Whether premature dual antiplatelet therapy (DAPT) interruption is safe in patients receiving cobalt chromium everolimus-eluting stents remains controversial. We sought to examine the relationship between DAPT discontinuation and stent thrombosis (ST) after cobalt chromium everolimus-eluting stents.Methods and Results-Outcomes from 11 219 patients were pooled from 3 randomized trials and 4 registries with 2-year follow-up period after cobalt chromium everolimus-eluting stent implantation. Rates of definite/probable ST were analyzed according to DAPT discontinuation in the following time intervals: 0 to 30, 30 to 90, 90 to 180, 180 to 365, and 365 to 730 days. Eighty-five cases of ST (0.75%) occurred in 83 patients during 2 years, with 41 (48.2%) events occurring within 30 days. the 2-year ST rate in patients interrupting DAPT at any time was similar to that in patients never interrupting DAPT through 2 years (25/4067 [0.63%] versus 58/7152 [0.83%] respectively; P=0.27]. By propensity and DAPT usage-adjusted multivariable analysis, permanent DAPT discontinuation before 30 days was independently associated with the occurrence of ST (hazard ratio [95% confidence interval], 26.8 [8.4-85.4]; P<0.0001), whereas permanent DAPT discontinuation in any interval after 90 days was not associated with ST. Only 2 ST events occurred after DAPT discontinuation between 30 and 90 days (both between 30 and 60 days), and the association between permanent DAPT discontinuation and ST during this period is unclear (hazard ratio [95% confidence interval], 8.7 [2.0-37.3]; P=0.004 for adjusted analysis and 3.4 [0.8-13.8]; P=0.07 for the unadjusted analysis).Conclusions-In this large pooled experience, permanent DAPT discontinuation before 30 days after cobalt chromium everolimus-eluting stent implantation was strongly associated with ST, whereas DAPT discontinuation beyond 90 days appeared safe.
ISSN: 1941-7640
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.